Condition 1: Sequelae of fracture of arm. Condition 2: Sequelae of other fractures of lower limb. Sequelae of injury classifiable to S42.-, S52.- and T10 Sequelae of injury classifiable to S82.-, S92.- and T12
Conditions
Interventions
Intervention 1: Intervention 2: Placebo. Intervention 2: Intervention 1: Penthrox inhaler, the recommended dose is 6 milliliters, one time. It is manufactured and marketed by Medical Developments Inte
Placebo
Treatment - Drugs
Intervention 1: Penthrox inhaler, the recommended dose is 6 milliliters, one time. It is manufactured and marketed by Medical Developments International (Melbourne, Victoria, Australia). Penthrox is
Sponsors
Vice chancellor for research, Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients older than 18 years who have had limb fractures. Exclusion criteria: Patients with a history of allergy to inhaled medications, severe injuries, including a ruptured liver and the kidneys, liver disease, kidney disease, patient dissatisfaction and age under 18 and over 80 years as well as patients with a decreased level of consciousness
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Before intervention, 5, 10, 20 and 30 minutes after intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Times of pain reduction. Timepoint: Before intervention, 5, 10, 20 and 30 minutes after intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Saghafinia
Baqiyatallah university of medical sciences
Outcome results
None listed